Positron Emission Tomography in Urology

EAU-EBU Update Series

Volumn 5, Issue 3, 2007, Pages 93-104

  de Jong, Igle J ^a   Breeuwsma, Anthonius J ^a   Pruim, Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Molecular imaging; Oncological urology; PET; Urology

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; CHOLINE C 11; ETHYLCHOLINE F 18; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; FLUTAMIDE; METHIONINE C 11; METHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER DYSFUNCTION; BONE METASTASIS; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG UPTAKE; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PENIS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TESTIS CANCER; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

EID: 34247216222     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2007.01.002     Document Type: Review

References (68)

1. Brown R.S., and Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72 (1993) 2979-2985
2. Rohren E.M., and Lowe V.J. Update in PET imaging of nonsmall cell lung cancer. Semin Nucl Med 34 (2004) 134-153
3. Juweid M.E., and Cheson B.D. Role of Positron Emission Tomography in Lymphoma. J Clin Oncol 23 (2005) 1-4
4. Bomanji J.B., Costa D.C., and Ell P.J. Clinical role of positron emission tomography in oncology. Lancet Oncol 2 (2001) 157-164
5. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., and Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33 (1992) 1972-1980
6. Katz-Brull R., and Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16 (1996) 1375-1380
7. Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 28 (2001) 117-122
8. Lee F.T., and Scott A.M. Immuno-PET for tumor targeting. J Nucl Med. 44 (2003) 1282-1283
9. Alhstrom H., Malmstrom P.U., Letocha H., Andersson J., Lanhstrom B., and Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 2 (1996) 180-185
10. Letocha H., Alhstrom H., Malmstrom P.U., Westlin J.E., Fasth K.J., and Nilsson S. Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy respons in muscle invasive transitional cell carcinoma of the urinary bladder. Br J Urol 74 (1994) 767-774
11. Heicappell R., Muller-Mattheis V., Reinhardt M., Vosberg H., Gerharz C.D., Muller-Gartner H., et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36 (1999) 582-587
12. Bachor R., Kotzerke J., Reske S.N., and Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 38 (1999) 46-50
13. Drieskens O., Oyen R., Van Poppel H., Vankan Y., Flamen P., and Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1412-1417
14. de Jong I.J., Pruim J., Elsinga P.H., Jongen M.M., Mensink H.J., and Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 29 (2002) 1283-1288
15. Picchio M., Treiber U., Beer J.A., Metz S., Bössner P., et al. Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings. J Nucl Med 47 (2006) 938-944
16. Gofrit O.N., Mishani E., Orevi M., Klein M., Freedman N., Pode D., et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 176 (2006) 940-944
17. Hricak H., Dooms G.C., Jeffrey R.B., et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162 (1987) 331-336
18. Platt J.F., Bree R.L., and Schwab R.E. The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol 149 (1987) 315-318
19. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
20. Effert P.J., Bares R., Handt S., Wolff J.M., Bull U., and Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
21. Laubenbacher C., Hofer C., Avril N., et al. F-18 FDG PET for differentiation of local recurrent prostate cancer and scar. J Nucl Med 36 Suppl 5 (1995) 198P
22. Shreve P.D., Grossman H.B., Gross M.D., and Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199 (1996) 751-756
23. Yeh S.D.J., Imbracio M., Garza D., and Kalaigian H. Twenty percent of bony metastases of hormonal resistant prostate cancer are detected by PET-FDG whole body scanning. J Nucl Med 36 Suppl 5 (1995) 198P
24. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43 (2002) 181-186
25. 11C-choline positron emission tomography. Eur Urol 42 (2002) 18-23
26. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
27. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27 (2000) 1415-1419
28. Reske S.N., Blumstein N.M., neumaier B., Gottfried H.W., et al. Imaging Prostate Cancer with 11C-Choline PET/CT Reske et al. J Nucl Med 47 (2006) 1249-1254
29. de Jong I.J., Pruim J., Elsinga P.H., Vaalburg W., and Mensink H.J. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44 (2003) 331-335
30. Nunez R., Macapinlac H.A., Yeung H.W., et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43 (2002) 46-55
31. Toth G., Lengyel Z., Balkay L., Salah M.A., Tron L., and Toth C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 173 (2005) 66-69
32. Zanzonico P.B., Finn R., Pentlow K.S., et al. PET-based radiation dosimetry in man of 18Ffluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 45 (2004) 1966-1971
33. Dehdashti F., Picus J., Michalski J.M., Dence C.S., Siegel B.A., Katzenellenbogen J.A., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 (2005) 344-350
34. Fichtner J., and Miller K. Management of patients with increasing PSA values after curative therapy. Urologe A 39 (2000) 475-482
35. Kotzerke J., Volkmer B.G., Neumaier B., Gschwend J.E., Hautmann R.E., and Reske S.N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1380-1384
36. Oyama N., Miller T.R., Dehdashti F., Siegel B.A., Fischer K.C., Michalski J.M., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
37. Fricke E., Machtens S., Hofmann M., van den Hoff J., Bergh S., Brunkhorst T., et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
38. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44 (2003) 32-39
39. Picchio M., Messa C., Landoni C., Gianolli L., Sironi S., Brioschi M., et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 169 (2003) 1337-1340
40. Heinisch M., Dirisamer A., Loidl W., Stoiber F., Gruy B., Haim S., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol Imaging Biol 8 (2006) 43-48
41. Rydh A., Lundblad M., Ahlstrom K.R., Tavelin B., and Stattin P. MRI of the skeleton in prostate cancer staging. Scand J Urol Nephrol 37 (2003) 222-225
42. Yeh S.D., Imbriaco M., Larson S.M., Garza D., Zhang J.J., Kalaigian H., et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23 (1996) 693-697
43. Morris M.J., Akhurst T., Osman I., Nunez R., Macapinlac H., Siedlecki K., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59 (2002) 913-918
44. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., and Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47 (2006) 287-297
45. Wahl R.L., Harney J., Hutchins G., et al. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose pilot animal and human studies. J Urol 146 (1991) 1470-1474
46. Bachor R., Kotzerke J., Gottfried H.W., Brandle E., Reske S.N., and Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 35 (1996) 146-150
47. Ramdave G.W., Thomas S.U., Berlangieri, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166 (2001) 825-830
48. Kang D.E., White Jr. R.L., Zuger J.H., et al. Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. J Urol 171 (2004) 1806-1809
49. Aide N., Cappele O., Bottet P., Bensadoun H., Regeasse A., Comoz F., et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30 (2003) 1236-1245
50. Lawrentschuk N., Poon A.M., Foo S.S., et al. Assessing regional hypoxia in human renal tumours using 18Ffluoromisonidazole positron emission tomography. BJU Int 96 (2005) 540-546
51. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663-1671
52. Kavolius J.P., Mastorakos D.P., Pavlovich C., et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
53. Safaei A., Figlin R., Hoh C.K., et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 57 (2002) 56-62
54. Majhail N.S., Urbain J.L., Albani J.M., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21 (2003) 3995-4000
55. Albers P., Bender H., Yilmaz H., Schoeneich G., Biersack H.J., and Mueller S.C. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53 (1999) 808-811
56. Cremerius U., Wildberger J.E., Borchers H., Zimny M., Jakse G., Gunther R.W., et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 54 (1999) 900-904
57. Hain S.F., O'Doherty M.J., Timothy A.R., Leslie M.D., Partridge S.E., and Huddart R.A. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 27 (2000) 590-594
58. Spermon J.R., De Geus-Oei L.F., Kiemeney L.A., Witjes J.A., and Oyen W.J. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89 (2002) 549-556
59. Lassen U., Daugaard G., Eigtved A., Hojgaard L., Damgaard K., and Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 30 (2003) 396-402
60. Stephens A.W., Gonin R., Hutchins G.D., and Einhorn L.H. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14 (1996) 1637-1641
61. Hain S.F., O'Doherty M.J., Timothy A.R., Leslie M.D., Harper P.G., and Huddart R.A. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83 (2000) 863-869
62. Bokemeyer C., Kollmannsberger C., Oechsle K., Dohmen B.M., Pfannenberg A., Claussen C.D., et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 86 (2002) 506-511
63. Becherer A., De Santis M., Karanikas G., Szabo M., Bokemeyer C., Dohmen B.M., et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54 (2005) 284-288
64. Scher B., Seitz M., Reiser M., Hungerhuber E., Hahn K., Tiling R., et al. 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 46 (2005) 1460-1465
65. Blok B.F., Willemsen A.T., and Holstege G. A PET study on brain control of micturition in humans. Brain 120 (1997) 111-121
66. Blok B.F., Sturms L.M., and Holstege G. Brain activation during micturition in women. Brain 121 (1998) 2033-2042
67. Kitta T., Kakizaki H., Furuno T., Moriya K., Tanaka H., Shiga T., et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. J Urol. 175 (2006) 994-998
68. Blok B.F., Sturms L.M., and Holstege G. A PET study on cortical and subcortical control of pelvic floor musculature in women. J Comp Neurol 389 (1997) 535-544